Granulocyte-macrophage colony-stimulating factor (GM-CSF) in inflammatory lung diseases: pathogenic contributor and therapeutic target
DOI:
https://doi.org/10.17179/excli2026-9692Keywords:
Granulocyte-macrophage colony-stimulating factor, asthma, COPD, lung cancer, inflammationAbstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an integral pathogenic factor in inflammatory lung pathologies including asthma, COPD, and lung cancer. As a pro-inflammatory cytokine, GM-CSF triggers the division and stimulation of granulocytes and macrophages, exacerbating the inflammatory response and promoting lung tissue damage. GM-CSF is an essential factor in promoting the production of the corresponding cytokines, levelling the effect of local activity by stimulating the infiltration of immune cells and maintaining chronic inflammation. Therefore, its neutralization in many ways leads to the cessation of the progression and exacerbation of inflammation in the lungs of patients with corresponding pathologies. Inhibitory therapy associated with GM-CSF reduces the number of immune cells and activates them at the inflammatory focus. The use of neutralizing antibodies to treat an acute inflammatory process is promising because they relatively quickly neutralize the effect of pathogenic GM-CSF. However, the immunocyte response can also be inhibited at the level of formation. Therapy with GM-CSF inhibitors can significantly reduce acute inflammation but can lead to adverse changes in the innate immunity of the patient. This review highlights GM-CSF's dual function of GM-CSF as a pathogenic contributor and possible treatment targets.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Muhammad Afzal, Sami I. Alzarea, Imran Kazmi, Abida Khan, Surya Nath Pandey, Arcot Rekha, Rakhi Mishra, Deepika Raina, Jyoti Maithani Kalra, Kapil Kalra, Gaurav Gupta, Md Sadique Hussain

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
- The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
- The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
- Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
- The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).
